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Abstract
Background: To examine the baseline metabolic monitoring (MetMon) for second generation
antipsychotics (SGA) among patients with schizophrenia in the Veterans Integrated Service
Network (VISN) 16 of the Veterans Health Administration (VHA).
Methods: VISN16 electronic medical records for 10/2002-08/2005 were used to identify patients
with schizophrenia who received a new episode of SGA treatment after 10/2003, in which the VISN
16 baseline MetMon program was implemented. Patients who underwent MetMon (MetMon+:
either blood glucose or lipid testing records) were compared with patients who did not (MetMon-
), on patient characteristics and resource utilization in the year prior to index treatment episode.
A parsimonious logistic regression was used to identify predictors for MetMon+ with adjusted odds
ratios (OR) and 95% confidence intervals (CI).
Results: Out of 4,709 patients, 3,568 (75.8%) underwent the baseline MetMon. Compared with
the MetMon- group, the MetMon+ patients were found more likely to have baseline diagnoses or
mediations for diabetes (OR [CI]: 2.336 [1.846-2.955]), dyslipidemia (2.439 [2.029-2.932]), and
hypertension (1.497 [1.287-1.743]), substance use disorders (1.460 [1.257-1.696]), or to be
recorded as obesity (2.052 [1.724-2.443]). Increased likelihood for monitoring were positively
associated with number of antipsychotics during the previous year (FGA: 1.434 [1.129-1.821]; SGA:
1.503 [1.290-1.751]). Other significant predictors for monitoring were more augmentation
episodes (1.580 [1.145-2.179]), more outpatient visits (1.007 [1.002-1.013])), hospitalization days
(1.011 [1.007-1.015]), and longer duration of antipsychotic use (1.001 [1.001-1.001]). Among the
MetMon+ group, approximately 38.9% patient had metabolic syndrome.
Discussion: This wide time window of 180 days, although congruent with the VHA guidelines for
the baseline MetMon process, needs to be re-evaluated and narrowed down, so that optimally the
monitoring event occurs at the time of receiving a new episode of SGA treatment. Future research
will examine whether or not patients prescribed an SGA are assessed for metabolic syndrome
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following the index episode of antipsychotic therapy, and whether or not such baseline and follow-
up monitoring programs in routine care are cost-effective.
Conclusion: The baseline MetMon has been performed for a majority of the VISN 16 patients with
schizophrenia prior to index SGA over the study period. Compared with MetMon- group,
MetMon+ patients were more likely to be obese and manifest a more severe illness profile.
Background
It has long been known that psychiatric patients experi-
ence increased morbidity and mortality associated with a
range of physical disorders including diabetes and cardio-
vascular disorders (CVD) [1]. Individuals with schizo-
phrenia are more likely to be overweight or obese than the
population at large [2-4]. Obesity further increases
patients' risk of cardiovascular morbidity and mortality.
Before the introduction of the antipsychotic drugs, it was
acknowledged that patients with schizophrenia may be at
a higher risk to develop diabetes (overall prevalence of
diabetes of 12.9% to 18.9%) than the general population
in similar age groups without schizophrenia (a prevalence
of 3% to 5.5%) [5,6]. Among people with schizophrenia,
there is a high prevalence of obesity, which is known as a
risk factor for diabetes [7]. Further, the results of a recent
study showed that compared with the general population,
people with major mental illness lose an average of more
than 25 years of potential life, primarily due to cardiovas-
cular disease [8].
Second-generation antipsychotics (SGA) or atypical drugs
have gained widespread acceptance for the management
of patients with schizophrenia and have been demon-
strated to have some advantages over first-generation
antipsychotics (FGA) or typical drugs. However, treatment
with several SGAs has been associated with increased
prevalence of diabetes, obesity, and dyslipidemia [9],
which are risk factors for cardiovascular diseases [10-12].
Several expert consensus guidelines calling for routine
monitoring of weight, lipids, and glucose have been
developed in the recent years such as those from the
Mount Sinai Conference on Medical Monitoring [13] and
the American Diabetes Association/American Psychiatric
Association Consensus Development Conference on
Antipsychotic Drugs and Obesity and Diabetes [14].
Despite the availability of the census guidelines, mentally
ill patients often do not receive adequate recognition of,
monitoring of, or care for their physical health conditions.
It is clear that patients across settings are not being ade-
quately monitored for the presence of metabolic disease
[15]. A retrospective cohort study of 4 state Medicaid pro-
grams (California, Oregon, Tennessee, and Utah) indi-
cated that glucose and lipid screenings were underutilized
in patients receiving a new episode of SGA drug therapy (<
20% baseline glucose testing and < 10% lipid testing)
[16]. A Canadian chart review study using the HIV clinic
as a control for monitoring of hypertension, diabetes, and
dyslipidemia reported that metabolic risk factors were less
frequently documented in mental health clinics [17].
Current concern about the need to enhance the quality of
health care for mental illness and the availability of con-
sensus guidelines have led clinicians, researchers, and
administrators in the VISN 16 network (the largest net-
work among all 22 VHA VISNs) to develop the first VHA
routine baseline metabolic monitoring (MetMon) pro-
gram for metabolic safety in patients treated with antipsy-
chotic drugs as a network-wide performance measure in
October 2003 [[18], detailed data available upon request].
The VISN 16 mental health leaders worked together to
define measures for performance of guideline-recom-
mended baseline monitoring at the time of new antipsy-
chotic starts. Specifically, in Fiscal Year (FY04), the VISN
16 Mental Health Product Line implemented 2 perform-
ance measures: 1) the proportion of patients at each facil-
ity that were newly started on an antipsychotic and had
weight recorded within 180 days prior to or 30 days after
the new antipsychotic was prescribed; and 2) the propor-
tion of patients that had blood glucose monitored in the
same time frame. A performance measure for baseline
lipid monitoring was added in FY05. The fully successful
level for a VA facility was defined as 85% in FY04 and 90%
in FY05 for weight, 75% to 78% for glucose, and 70% in
FY05 for lipids respectively. With a sample size of 4,066
patients with new antipsychotic starts in FY03, and 4,019
in FY04, the average facility rate of weight monitoring was
87.9% in 2003 and 92.2% in FY04, with 8 out of 10 facil-
ities performing at the "fully successful" level. In FY04, 8
facilities were "fully successful" at implementing the
blood glucose performance measure. The rate of baseline
lipid monitoring in FY05 was 63.3% (compared with
59.3% in FY04). Overall, implementation of the baseline
MetMon has reduced the variations in the VISN 16 health
system factors such as settings and lack of access, which
could be attributed to the reasons why some patients are
not monitored, and provided a unique opportunity to
focus on the patient-level characteristics in our study.
In an effort to improve patient care by increasing meta-
bolic monitoring, this study sought to identify patient
characteristics that are associated with decreased baseline
MetMon. Specifically, this retrospective study amongBMC Psychiatry 2009, 9:80 http://www.biomedcentral.com/1471-244X/9/80
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VISN 16 patients with schizophrenia who received a new
episode of SGA treatment aimed to identify predictors
(patient demographic and illness characteristics, antipsy-
chotic use patterns, and health care resource utilization)
of undergoing the baseline MetMon.
Methods
After obtaining Tulane/VHA IRB and VHA Research and
Development (R&D) approvals for this study protocol,
the VISN 16 data warehouse was used to evaluate antipsy-
chotic medication patterns and health outcomes. We
examined metabolic monitoring in a retrospective cohort
study in patients with schizophrenia receiving care from
the Veterans Health Administration, US Department of
Veterans Affairs (VA) which is an integrated health system
providing comprehensive health care services. Patients'
demographic information, inpatient care, outpatient care,
outpatient pharmacy records, vital signs, and laboratory
results during the period of October 2002 through Sep-
tember 2005 in VISN 16 were extracted from the VISN 16
data warehouse. Data format and content which was
stripped of patient identifiers was in compliance with the
Health Insurance Portability and Accountability Act
(HIPAA) requirements.
The baseline metabolic monitoring services in the study
were required to occur within 180 days prior to a new SGA
treatment episode (i.e., the index date). The evaluation
method had intentionally excluded the first 30 days after
the new episode of SGA was prescribed to avoid potential
misattribution of pre-existing metabolic syndrome to the
index drug. It was previously shown that rapid weight gain
can occur early on - within the first 2-3 weeks of treatment
- particularly with certain SGA such as olanzapine [19,20].
Such rapid and early weight gain could lead to increase
the probability that some patients who did not have a pre-
existing metabolic syndrome might have met the meta-
bolic syndrome criteria within the first 30 days after a new
treatment episode. Due to a retrospective study design, it
was hard to ascertain whether lab testing belonged to
baseline monitoring or follow-up care during the first
month following the prescribed index SGA was filled by
patients.
Treatment episode with any SGA reflected 3 different
types of treatment episodes: switch, new start, and aug-
mentation. The switch episode was defined by the discon-
tinuation of the previous antipsychotic agent within 60
days after the index date. A new start episode was defined
by receiving a new episode of antipsychotic agent after a
medication break of at least 60 days. An augmentation
episode was defined by the concurrent use of the new
antipsychotic agent and the previous antipsychotics for
longer than 60 days. Only was the first antipsychotic epi-
sode included if there were multiple episodes for a
patient.
Additional file 1 presents the process leading to the ana-
lytical sample. We initially identified 8,816 patients who
had at least 1 record of antipsychotic prescription after
October 2003 in order to ensure that all patients at least
had 1 year before the earliest possible index date (October
2002-September 2003). All patients also had a diagnosis
of schizophrenia based on the codes of the International
Classification of Diseases, 9th Revision, Clinical Modifi-
cation (ICD-9-CM: 295.xx) for either at least 1 inpatient
service or at least 2 outpatient visits. Patients were
excluded if they were diagnosed with a bipolar disorder
(ICD-9-CM code: 296.0x, 296.4x, 296.5x, 296.6x, 296.7x,
296.8x, 296.9x) or any type of dementia (ICD-9-CM code:
294.1x, 290.4x). We excluded non-treatment episodes (n
= 2,354) who had been on only 1 antipsychotic drug with-
out any break in therapy for more than 30 days during the
whole study period. These excluded patients may not
present as the target candidates for the VISN 16 antipsy-
chotic monitoring program because the baseline MetMon
required a new treatment episode. Therefore, a total of
6,462 patients had at least 1 new treatment episode, start-
ing from the index date when the patient started a new
antipsychotic agent. We further excluded patients who
only had 1 filled prescription (n = 393), received more
than 2 index antipsychotic drugs (n = 677), or switched to
an FGA agent (n = 683).
The analytical sample of 4,709 patients was used to iden-
tify 2 comparison cohorts. One cohort (n = 3,568)
included patients who received the baseline MetMon (at
least 1 claims record or medical record of blood glucose
testing or lipid panel) within 6 months before the index
date (MetMon+) and another cohort (n = 1,141) included
those who did not (MetMon-). All treatment episodes
were further classified by type of episodes (switch, new
start, and augmentation).
The MetMon+ and MetMon- groups were compared on
several variables assessed during the pre-existing year (i.e.,
during the year prior to starting a new antipsychotic epi-
sode). These variables included the socio-demographics
(age, gender, race, and insurance coverage other than
VHA), illness characteristics including the Charlson
Comorbidity Index (CCI) based on ICD-9-CM codes [21]
and ICD-9-CM diagnosis of substance (drug and/or alco-
hol) dependence disorders, antipsychotic medication use
patterns in the pre-existing year including the duration
and medication possession ratio (MPR) of antipsychotic
agents, numbers of SGAs, and use of SGA+FGA combina-
tion. We also compared the 2 cohorts on outpatient visits
(psychiatric or nonpsychiatric) during 1 year prior to the
index date. For inpatient care records, the count of hospi-
tal admission as a confounder was examined during the
180 days before receiving the baseline MetMon services
because glucose and lipid testing may be more likely toBMC Psychiatry 2009, 9:80 http://www.biomedcentral.com/1471-244X/9/80
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have been performed during a recent hospitalization over
the same timeframe of 6 months than otherwise.
For patients who underwent the baseline MetMon, we
also examined 5 cardio-metabolic risk factors: (1) pres-
ence of serum high density lipoprotein (HDL) cholesterol
level <40 mg/dl (male) or <50 mg/dl (female); (2) fasting
plasma glucose (FPG) level of at least 110 mg/dl; (3)
serum triglyceride (TC) level of at least 150 mg/dl; (4)
blood pressure of at least 130/85 mm/Hg; and (5) waist
circumference of more than 102 cm (>40 inches) for men
and >88 cm (>35 inches) for women. Since waist circum-
ference was rarely reported in the medical records, we
replaced it with a body mass index (BMI) ≥ 28.8 because
it was found to be correlated with a waist circumference of
102 cm for men and 88 cm for women [22,23]. In addi-
tion, we further reported a recent BMI in 4 categories:
underweight (<18.5), normal (18.5-24.9), overweight
(25.0-29.9), and obese (≥ 30.0), which is the weight cate-
gorization used by the National Heart, Lung, and Blood
Institute [24]. For those without the baseline MetMon, we
reported their most recent values of blood pressure and
BMI prior to the index date. Using the lab testing-based
indicators, we created a dichotomous variable reflecting
whether a patient met the criteria for metabolic syndrome
as defined by the National Cholesterol Education Pro-
gram (NCEP) (at least 3 out of 5 parameters) or not (2 or
less indicators) in 2 methods. To meet the metabolic syn-
drome using method 1, it was required to include patients
who had all 5 indicators with no missing lab tests. Fur-
thermore, while keeping the same sample as method 1,
method 2 was used to expand the lab testing-based indi-
cators to the composite indicators, which include all 3
types of records: lab results, diagnosis codes (diabetes,
dyslipidemia, hypertension), and medication uses (antid-
iabetics, lipid-lowering drugs, and antihypertensives).
Because the NCEP criteria has 2 lipid-related indicators
(HDL and triglyceride), to be conservative, either dyslipi-
demia diagnosis or lipid-lowering drugs for a patient was
counted as only 1 positive lipid indicator rather than 2.
The variables, in which the 2 cohorts were shown to sig-
nificantly differ in the year prior to the index date through
t-tests or chi-square tests, were then fit into a parsimoni-
ous logistic regression to identify predictors for undergo-
ing the baseline MetMon. Specifically, a step-wise
progression method was used to select the most parsimo-
nious multivariate model. All analyses were performed
using the SAS version 9.13. The statistical significance was
set at the level of 0.05.
Results
Among 4,709 patients in the analytical sample, 75.77%
(n = 3,568) received the baseline MetMon during the 180
days before the new antipsychotic episode. The MetMon+
group had 2,815 patients (78.90%) with new start epi-
sodes, 439 patients (12.30%) with switch episodes, and
314 patients (8.80%) with augmentation episodes. The
MetMon- group had 986 patients (86.42%) with new start
episodes, 97 (8.50%) with switch episodes, and 58 with
augmentation episodes (5.08%).
Additional file 2 presents the baseline demographic and
illness characteristics for these 2 cohorts. Although the
MetMon- and MetMon+ groups did not significantly dif-
fer in gender or ethnicity, the MetMon+ patients were
more likely to have non-VHA insurance coverage, higher
CCI scores, diagnoses of diabetes, dyslipidemia, hyperten-
sion, or substance use disorders, more outpatient office
visits (psychiatric, nonpsychiatric, and either) during the
prior year, more hospital admissions during the 180 days
before the start of a treatment episode, and were signifi-
cantly older. The hospitalization days for the MetMon+
group was twice as long as that for the MetMon- group
(12.96 days vs. 6.37 days, p < .0001). Finally, there was a
significant difference in the MetMon rates across 3 calen-
dar years for each index date.
Additional file 3 summarizes the pre-existing antipsy-
chotic use patterns for the 2 cohorts. The MetMon+ group
had been intensively treated by antipsychotic agents.
These patients were associated with significantly longer
treatment duration, a higher medication possession ratio,
and a higher number of different antipsychotic drugs.
Additional file 4 presents the cardio-metabolic risk factors
for the 2 cohorts. The MetMon+ group had a significantly
higher rate of BMI ≥ 28.8 (39.43% vs. 18.58%, p < .0001),
while the rate of high blood pressure was comparable
across comparison cohorts. MetMon+ patients had met at
least 3 criteria out of 5 parameters for metabolic syn-
drome in the pre-existing period. The prevalence rates of
metabolic syndrome among the MetMon+ group varied
with different methods: method 1 (22.69%) and method
2 (38.89%). Using the method 2, 7.19% MetMon-
patients can be also classified to have metabolic syn-
drome, based on the diagnosis and medication use infor-
mation.
Additional file 5 presents a parsimonious logistic regres-
sion model (in adjusted odds ratio [95% confidence inter-
val]) to identify the predictors of undergoing the baseline
metabolic monitoring services. Having the baseline diag-
nosis or medication use for diabetes, dyslipidemia, hyper-
tension, or a higher BMI (i.e., BMI ≥ 28.8) was among the
strongest predictors for undergoing the baseline MetMon.
Specially, baseline dyslipidemia, diabetes and higher BMI
almost more than doubled the likelihood of undergoing
the baseline MetMon (dyslipidemia: 2.439 [2.029-
2.932]), diabetes 2.336 [1.846-2.955]), high BMI (2.052BMC Psychiatry 2009, 9:80 http://www.biomedcentral.com/1471-244X/9/80
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[1.724-2.443]). A comorbidity condition of baseline
hypertension increased the likelihood of baseline moni-
toring by approximately 50% (1.497 [1.287-1.743]).
Patients with a diagnosis of substance dependence were
46.0% more likely to undergo the baseline MetMon
(1.460 [1.257-1.696]). Augmentation episode - a marker
of increased treatment complexity - was associated with a
58% higher likelihood of undergoing the baseline Met-
Mon (1.580 [1.145-2.179]). For each additional SGA
used, patients were 50% more likely to be monitored
(1.503 [1.290-1.751]), while for each additional FGA, an
increase in receiving MetMon was 43% higher (1.434
[1.129-1.821]). Other significant predictors included the
number of non-psychiatric outpatient office visits, hospi-
talization days, and the treatment duration with the most
recent antipsychotic agent, but they increased the likeli-
hood of monitoring by no more than 10%.
Discussion
The baseline metabolic monitoring program at the VHA's
largest region - VISN 16 - is an experiment with important
public health implications for disease management of
patients with schizophrenia. This monitoring program
was associated with a high rate (76%) of the baseline Met-
Mon for patients with schizophrenia who received a new
treatment episode of SGA. The MetMon rate and sample
size presented by this study are very similar to, and yet
slightly lower than, the VISN internal report, reflecting
that the first month post-index was not used to calculate
the baseline MetMon. It is also well known that the VHA
population is relatively older than a Medicaid or a com-
mercially insured population. Metabolic screening is
more likely to occur in older adults therefore one would
expect average VHA rates of screening to be higher than
average rates of screening in Medicaid or commercially
insured patients. Furthermore, a much higher baseline
MetMon rate reported in this study is not surprising in the
environment where the MetMon was required by the
VISN 16 Mental Health Product Line.
Despite a high rate of monitoring, patients who were not
monitored were significantly different from monitored
patients on a host of demographic, clinical, and resource
use variables. The monitored patients were as more than
twice as likely to be overweight or obese. The monitored
patients were also associated with baseline diagnoses and
treatments for diabetes, dyslipidemia, or hypertension, a
higher rate of substance use disorders, more outpatient
visits, a longer duration of antipsychotic use, and had pre-
viously used a larger number of different antipsychotic
drugs. Current findings suggest that the baseline MetMon
tends to take place among patients manifesting a more
severe illness profile and for those who may be considered
by their clinicians to be at a greater risk of metabolic syn-
drome due to being overweight or obese or having pre-
existing conditions. Interestingly, the monitored group
was not significantly more likely to be treated with any
specific SGA prior to new treatment episode of another
SGA.
The logistical regression model suggests that among the
11 variables that significantly differed between patients
with versus without the baseline MetMon, there was a
small and distinct set of 8 variables that best predicted
undergoing the monitoring process prior to on the index
date of SGA. These are 3 pre-existing metabolic condi-
tions, higher BMI, augmentation with another SGA, mul-
tiple antipsychotic drugs, diagnosis of substance
dependence, and psychiatric hospitalization prior to the
index date of SGA. Importantly, the presence of pre-exist-
ing conditions or obesity (BMI ≥ 28.8) was among the set
of strongest predictors, as each of them almost doubled
the likelihood of undergoing the baseline MetMon. How-
ever, the disparities between the groups were not signifi-
cantly related to either race or gender.
Current findings also show that among the monitored
patients, approximately 38.9% of MetMon+ patients were
identified as having metabolic syndrome as defined by the
NCEP using the composite indicators. This rate is very
close to the one previously found for patients with schiz-
ophrenia. Results from a large randomized, double-blind
study sponsored by the National Institute of Mental
Health (NIMH) - the Clinical Antipsychotic Trials of Inter-
vention Effectiveness (CATIE) found that at baseline
40.9% (of 689 participants) had a metabolic syndrome
based on the NCEP criteria and 42.7% based on the FPG
≥ 100 mg/dl [15]. In addition to the difference in moni-
toring rate (per-protocol 100% in the CATIE study and
76% of this study), the other reasons for the observed dif-
ference are unclear, but may be related to differences in
methodology, because the VHA patients, despite undergo-
ing the baseline MetMon in the 180 days prior to the
index date, could have developed a metabolic syndrome
during the relatively long ensuing time between the mon-
itoring event and the new treatment episode. This wide
time window of 180 days, although congruent with VHA
guidelines for the routine baseline MetMon process, needs
to be re-evaluated and narrowed down, so that optimally
the monitoring event occurs at the index date. Although
the NCEP definition of "metabolic syndrome" includes an
FPG of ≥ 110 mg/dl, the ADA has since changed their
threshold for a diagnosis of impaired fasting glucose to at
least 100 mg/dl [25,26]. This new cutpoint should be
applicable to this study for identifying the lower FPG
boundary as 1 criterion for metabolic syndrome. The Met-
Mon was defined as glucose or lipid testing. Based on
Additional file 4, all MetMon+ subjects had glucose test-
ing and 80% of those also had lipid testing. The pattern
may reflect the sequential approach of implementing theBMC Psychiatry 2009, 9:80 http://www.biomedcentral.com/1471-244X/9/80
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monitoring (weight and glucose in FY04 and all monitor-
ing in FY05). It would be interesting to know the charac-
teristics of those patients who did not get the lipid testing
in the future research. Furthermore, caution is needed in
the interpretation of the reported rate of metabolic syn-
drome among the MetSyn- patents, which is very low
because of no lab testing for this group.
Further studies on the management of schizophrenia with
comorbid metabolic syndrome are also warranted so that
effective interventions may be developed to improve the
quality of care for this particular group of patients at high
risk of cardiovascular diseases. By routinely performing
physical health monitoring, referrals, and/or treatment
for patients with schizophrenia, the current system of frag-
mented mental and physical health services could be
transformed into a system focusing on early interventions
[27].
To our knowledge, there are no published studies on the
rate of baseline MetMon for patients with schizophrenia
in a large health care system after the guideline-based
baseline MetMon has been implemented as a perform-
ance indicator, nor is the information currently available
on the proportion of patients who are identified via the
baseline MetMon to have a metabolic syndrome. No dis-
parities in the monitoring services have existed in terms of
gender and race. Age disparity in the univariate analysis
appeared to be due to the large sample size for each com-
parison cohort. The baseline MetMon was designed as a
VISN 16 network quality improvement indicator, yet
there were still about 25% patients who did not receive
the baseline MetMon. In clinical practice, the MetMon has
been found very low in both Medicaid and privately
insured populations [16,28,29]. The inclusion of BMI as
an indicator of who received testing and who did not is
quite unique for this study. This measure has not been
available for study in the previous studies examining Med-
icaid and commercially-insured patients, and the VA
results indicate that BMI is a strong risk determinant of
who received testing. Beyond the issue of whether or not
the patients have received the appropriate tests before a
new treatment episode of SGA, a more important issue for
future research is whether or not patients prescribed an
SGA are assessed for metabolic syndrome following the
new episode of drug therapy, and whether or not such
baseline and follow-up monitoring programs in the rou-
tine care are cost-effective. In addition to those patient-
level factors found in this study, the factors (either barriers
or facilitators) at the facility or system level would require
further clarification in future research.
Current findings need to be evaluated in the context of the
study's limitations. First, the definition of "baseline" per
VHA guidelines could be up to 6 months prior to the
index date. As noted earlier, this time frame is too long,
likely allowing for the development of a metabolic syn-
drome during the ensuing time between the "baseline"
MetMon and the index date. Second is our reliance on ret-
rospective claims database analyses to assess the baseline
MetMon and presence of a metabolic syndrome.
Although the VA received care from the VA system as an
integrated system, patients with non-VA insurance whose
data on lab testing ordered by a non-VA provider were not
necessarily linked with the study dataset unless the
records were submitted into the VA as patient's medical
records. We are not clear about the magnitude of underre-
porting as a source of misclassification bias. A prospective
study would have been preferable as it would have yielded
more complete and accurate data. Considering the high
cost of conducting large prospective studies, another
potential approach for future research may involve the use
of the VHA electronic medical records (EMR) as a data col-
lection tool for a prospective observational study. These
records have more detailed and relevant clinical informa-
tion, which is rarely captured in claims-based databases. A
third limitation is our use of BMI instead of waist circum-
ference, the metabolic parameter required in the NCEP
definition of a metabolic syndrome [26]. Fourth, the indi-
cators for metabolic syndrome were not collected during
the same clinic visit or at least recorded at the same date
in the database. We allowed all metabolic parameters to
be tested within 6 months before the start of a new SGA
episode and selected the results of the ones closest to the
index date. Finally, our analysis focused on patient-level
factors whereas other factors (either barriers or facilita-
tors) at the facility or system level could have also
impacted the likelihood of undergoing the baseline Met-
Mon, despite the quality improvement effort of the mon-
itoring program.
Conclusion
The current analysis of the baseline MetMon program at
the VHA's largest region (VINS 16) has found that a
majority of patients with schizophrenia who received a
new episode of SGA treatment had undergone the base-
line MetMon services prior to the index treatment. How-
ever, 25% of the patients were not monitored. The
monitored patients were, however, significantly different
from those who were not monitored on a host of baseline
demographic and clinical characteristics as well as on
prior use of health care services. Among these variables,
the set of best predictors of undergoing the baseline Met-
Mon were pre-existing related conditions and obesity.
Findings highlight the need for routine monitoring of
weight, lipids, and glucose in a systematic manner for all
persons receiving a new episode of antipsychotic treat-
ment, regardless of body weight, illness profile, or use of
health care services, and to do so at the outset of new epi-
sode.BMC Psychiatry 2009, 9:80 http://www.biomedcentral.com/1471-244X/9/80
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